Indication · Liver/metabolic disease
NASH/MASH
Also known as: non-alcoholic steatohepatitis · metabolic dysfunction-associated steatohepatitis
NASH/MASH has 4 mapped peptide assets across 2 targets.
Targets
View all →GLP-1R
Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.
Glucagon receptor
Activation increases hepatic glucose output and energy expenditure; biased/co-agonist approaches aim to preserve lipid oxidation and satiety without hyperglycemia.
Active assets by stage
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Retatrutide | Phase 3 | Eli Lilly |
| Survodutide | Phase 2 | Boehringer Ingelheim, Zealand Pharma |
| Pemvidutide | Phase 2 | Eli Lilly |
| Efinopegdutide | Phase 2 | Eli Lilly |
Trials
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT05567796 | Phase 3 | A Study of Retatrutide in Participants With Obesity or Overweight | Recruiting |
| NCT05649174 | Phase 2 | A Study to Evaluate Survodutide in Participants With Non-alcoholic Steatohepatitis (NASH) | Active, not recruiting |